

JORNADAS EDUCATIVAS SOBRE ENFERMEDAD INFLAMATORIA INTESTINAL

PARA EL SERVICIO DE APARATO DIGESTIVO: ECCO 2024

22 de marzo, 5 de abril y 12 de abril de 2024

PROGRAMA

OBJETIVOS: Actualizar los conocimientos en enfermedad inflamatoria intestinal (enfermedad de Crohn y colitis ulcerosa) de los especialistas en aparato digestivo.

El programa repasa las comunicaciones enviadas al congreso de la ECCO 2024 (European Crohn's and Colitis Organisation) y las sesiones las impartirán los investigadores autores de dichas comunicaciones.

Estas sesiones cuentan con el patrocinio múltiple de la industria farmacéutica (multiesponsorizado).

VIERNES 22 DE MARZO

15:00: Frequency and effectiveness of dose de-escalation of biologic therapy in inflammatory bowel disease: The RAINBOW-IBD study of ENEIDA.

Ponente: Dra. María Chaparro

15:30: Frequency and effectiveness of dose escalation of biologic therapy in inflammatory bowel disease: The RAINBOW-IBD study of ENEIDA.

Ponente: Dra. María Chaparro

16:00: coffee break

16:15: Global perspectives on managing inflammatory bowel disease (IBD) during pregnancy and lactation: current state and the necessity for enhancement.

Ponente: Dra. María José Casanova

17:00 Finalización jornada

PATROCINAN:



VIERNES 5 DE ABRIL

- 15:00: Unrevealing new potential key mechanisms implicated in inflammatory bowel disease by multiomic approach.
- Ponente: Dra. Montserrat Baldán
- 15:30: A novel multiomic approach to unravel the mechanisms of action of biologics and tofacitinib in inflammatory bowel disease
- Ponente: Dra. Montserrat Baldán
- 16:00: coffee break
- 16:15: Novel biomarkers associated with inflammatory bowel disease.
- Ponente: Dra. Montserrat Baldán
- 17:00 Finalización jornada

VIERNES 12 DE ABRIL

- 15:00: Predictive biomarkers of therapeutic response in inflammatory bowel disease: a step towards personalized medicine
- Ponente: Dra. Montserrat Baldán
- 15:30: Faecal microbiota composition by shotgun metagenomic sequencing approach in a newly diagnosed cohort of inflammatory bowel disease patients: results from the IBDomics Project.
- Ponente: Dra. Macarena Orejudo
- 16:00: coffee break
- 16:15: Long-term outcomes of newly diagnosed inflammatory bowel disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU.
- Ponente: Dra. María Chaparro
- 17:00 Finalización jornada

PATROCINAN:

